Ardelyx Targets 2027 Profitability as IBSRELA Faces Insurance Hurdles

Ardelyx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Ardelyx is targeting GAAP profitability in 2027, with IBSRELA expected to be its main growth and cash-generation driver; executives did not disclose the anticipated profit level.
  • IBSRELA faces greater insurance and prior-authorization hurdles. Ardelyx reiterated 2026 sales guidance of $250 million to $270 million, implying roughly 30% growth, and is adding reimbursement support while considering modest payer concessions.
  • Enrollment is complete in a Phase 3 trial testing IBSRELA for chronic idiopathic constipation, with results expected in the second half of 2027. The indication could broaden the drug’s opportunity in a patient population two to three times larger than the current IBS-C market.
  • Five stocks to consider instead of Ardelyx.

Ardelyx NASDAQ: ARDX expects to reach profitability in 2027 as it works to sustain growth for IBSRELA while addressing insurance hurdles that have slowed prescription fulfillment, executives said at the Jefferies Healthcare conference in London.

President and CEO Mike Raab described the coming year as a pivotal transition for the company, calling IBSRELA the “engine of the future” for Ardelyx. CFO Sue Hohenleitner said the company is targeting profitability under generally accepted accounting principles, or GAAP, and has high confidence in achieving it next year. She did not specify the expected magnitude of profitability.

Ardelyx reiterated its 2026 IBSRELA sales guidance of $250 million to $270 million in the third quarter, after lowering the forecast in the second quarter as payer friction emerged. Hohenleitner said the revised range would represent growth in the 30% range, compared with the mid-50% growth implied by the initial forecast. The company also reiterated its XPHOZAH guidance of $110 million to $120 million.

Insurance hurdles and payer contracting

Raab said insurers have imposed more work on patients and health care providers seeking prior authorization for IBSRELA. He linked the change in market dynamics in part to a competitor, LINZESS, cutting its wholesale acquisition cost in half starting in the fourth quarter of the prior year.

“There are very few examples of a drug like IBSRELA being forbidden from being filled,” Raab said. “What they’re doing is causing more work to be done in order to get that prescription fulfilled for the patient.”

Requirements vary by payer, Raab said, ranging from a physician attestation to documentation of diagnostic criteria. Ardelyx has added 20 field reimbursement managers to help medical offices navigate the process and could make additional incremental investments in that team, he said.

Hohenleitner said payer contracting is one of several tools Ardelyx is considering, but any steps must offer a positive return on investment. The company reported a gross-to-net rate of about 32% for the quarter, she said, giving it some room to make concessions while seeking to preserve margins.

Raab said the company expects to make “modest and incremental” changes with payers rather than a major shift in pricing. He expects IBSRELA to remain a second- or third-line medication.

Constipation trial and long-term opportunity

Ardelyx has completed enrollment in a Phase 3 trial of IBSRELA for chronic idiopathic constipation, or CIC, with top-line data expected in the second half of 2027, executives said. Hohenleitner said the CIC population is two to three times the size of the current irritable bowel syndrome with constipation, or IBS-C, market, although many CIC patients are successfully treated with over-the-counter products.

Hohenleitner said an additional CIC indication could make prescribing simpler for physicians who currently must distinguish between the two conditions. A filing would follow the trial readout, she said.

Ardelyx remains confident that IBSRELA can reach $1 billion in sales, but has removed a specific timeframe for that goal, Hohenleitner said. She attributed the change to the product’s compound growth rate and said the question was when the company would reach the target.

Raab said Ardelyx does not expect a wholesale expansion of its sales force, although it could add staff incrementally, including around a potential CIC launch.

Cash and pipeline plans

Raab said XPHOZAH will remain a contributor, while IBSRELA is expected to drive cash generation and support the company’s expansion. He said Ardelyx intends to use future free cash flow to build its pipeline through partnerships or acquisitions.

Hohenleitner said Ardelyx had $285 million in cash at the end of September. Alongside the CIC trial and pediatric studies, the company is conducting work to support an investigational new drug application for preclinical candidate RDX10531.

Raab said Ardelyx is naturally looking for opportunities in its existing therapeutic areas, including gastrointestinal and renal medicine, but is also open to adjacent or other fields. He cited hepatology as one potential adjacency and said affordability remains an important consideration.

About Ardelyx (NASDAQ:ARDX)

Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ardelyx Right Now?

Before you consider Ardelyx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.

While Ardelyx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines